Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Background ROS1 fusion-positive (ROS1 +) nonsmall cell lung cancer (NSCLC) patients are highly sensitive to tyrosine kinase inhibitor (TKI) treatments. However, acquired TKI resistance remains the major hurdle preventing patients from experiencing prolonged benefits. Methods 107 advanced or metastat...
| Publicado en: | Clinical Chemistry Vol. 70; no. 4; pp. 629 - 642 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Oxford University Press / USA
Apr2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |